An Open Label Compassionate Use Trial of Ublituximab and TGR-1202 in Combination or as Single Agents in Subjects Currently receiving Treatment on Ublituximab and/or TGR-1202 Trials with B-cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia.
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
TG Therapeutics, Inc
Start Date
February 20, 2018
End Date
February 14, 2023
Administered By
Duke Cancer Institute
Awarded By
TG Therapeutics, Inc
Start Date
February 20, 2018
End Date
February 14, 2023